CMC Biologics, PATH Form mAb Pact
CMC Biologics, a clinical and commercial development and contract manufacture of therapeutic proteins,has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies as anti-malaria treatments.
Under the agreement, CMC Biologics will develop a CHEF1 production cell line and process for manufacture of MVI's monoclonal antibody, targeting circumsporozoite protein (CSP), for use by MVI in clinical research to study protection from P. falciparum infection. Process development will be conducted at CMC Biologics' Bothell, Washington facility and be transferred to its Berkeley, California facility for GMP manufacturing. Pending successful outcome, this study may lead to evaluation of additional monoclonal antibodies, targeting different epitopes, engineered to protect humans from infection.
Source: CMC Biologics